Alleles of the gene encoding IL-1α may predict control of plasma viraemia in HIV-1 patients on highly active antiretroviral therapy

AIDS

Volumn 18, Issue 11, 2004, Pages 1495-1501

  Price, Patricia ^a,b   James, Ian ^c   Fernandez, Sonia ^a,b   French, Martyn A ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

Antiretroviral therapy; HIV; IL1A; Polymorphism; Viral load

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; ZIDOVUDINE;

ADULT; AGE; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG CHOICE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-1; MALE; POLYMORPHISM, GENETIC; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIREMIA;

EID: 3843102584     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131352.06784.c6     Document Type: Article

References (29)

1. Phillips AN, Miller V, Sabin C, Cozzi Lepri A, Klauke S, Bickel M, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001; 15:2379-2384.
2. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003; 37:714-722.
3. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003; 17:1696-1798.
4. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003; 17:201-208.
5. O'Brien TR, McDermott DH, Ioannidis JP, Carrington M, Murphy PM, Havlir DV, Richman DD. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000; 14:821-826.
6. Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998; 12:2193-2202
7. Almeida CA, Price P, French MA. Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18:1351-1355.
8. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
9. Price P, Calder DM, Wilt CS, Allcock RJ, Christiansen FT, Davies GR, et al. Periodontal attachment loss in HIV-infected patients is associated with the major histocompatibility complex 8.1 haplotype (A1,B8,DR3). Tissue Antigens 1999; 54:391-399.
10. Jouvenne P, Chaudhary A, Buchs N, Giovine FS, Duff CW. Possible genetic association between interleukin-1alpha gene polymorphism and the severity of chronic polyarthritis. Eur Cytokine Network 1999; 10:33-36.
11. Price P, Morahan C, Huang D, Stone E, Cheong KYM, Rodgers M, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002; 16:2043-2047.
12. McDowell TL, Symons JA, Ploski R, Forre O, Duff CW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 a polymorphism. Arthr Rheum 1995; 38:221-228.
13. Kornman KS, Crane A, Wang HY, di Giovine FS, Newman MG, Pirk FW, et al. The interleukin-T genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24:72-77.
14. Cox A, Camp NJ, Nicklin MJ, di Giovine FS, Duff GW. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 1998; 62:1180-1188.
15. Shirodaria S, Smith J, McKay IJ, Kennett CN, Hughes FJ. Polymorphisms in the IL-1A gene are correlated with levels of interleukin-1alpha protein in gingival crevicular fluid of teeth with severe periodontal disease. J Dent Res 2000; 79: 1864-1869.
16. Rogers MA, Figliomeni L, Baluchova K, Tan AE, Davies G, Henry PJ, Price P. Do interleukin-1 polymorphisms predict the development of periodontitis or the success of dental implants? J Periodont Res 2002; 37:37-41.
17. Creenstein C, Hart TCH. A critical assessment of interleukin-1 (IL-1) genotyping when used in a genetic susceptibility test for severe chronic periodontitis. J Periodontol 2002; 73:231-247.
18. Karjalainen J, Hulkkonen J, Pessi T, Huhtala H, Nieminen MM, Aromaa A, et al. The IL1A genotype associates with atopy in nonasthmatic adults. J Allergy Clin Immunol 2002; 110: 429-434.
19. Karjalainen J, Joki-Erkkila VP, Hulkkonen J, Pessi T, Nieminen MM, Aromaa A, et al. The IL1A genotype is associated with nasal polyposis in asthmatic adults. Allergy 2003; 58:393-396.
20. Martinez LO, Agerholm-Larsen B, Wang N, Chen W, Tall AR. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem 2003; 278:37368-37374.
21. Schoonbroodt S, Ferreira V, Best-Belpomme M, Boelaert JR, Legrand-Poels S, Korner M, Piette J. Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J Immunol 2000; 164:4292-4300.
22. Dominici R, Cattaneo M, Malferrari C, Archi D, Mariani C, Grimaldi LM, Biunno I. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics 2002; 54:82-86.
23. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc Natl Acad Sci USA 1997; 94:508-513.
24. Pollock AS, Turck J, Lovett DH The prodomain of interleukin 1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB J 2003; 17:203-213.
25. Deshpande RV, Goust JM, Hogan EL, Banik NL. Calpain secreted by activated human lymphoid cells degrades myelin. J Neurosci Res 1995; 4:259-265.
26. Mori N, Prager D. Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood 1996; 87:3410-3417.
27. Kawaguchi Y, Hara M, Kamatani N, Wright TM. Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis. Arthr Rheum 2003; 48:193-202.
28. Cabral A, Fischer DF, Vermeij WP, Backendorf C. Distinct functional interactions of human Skn-1 isoforms with Ese-1 during keratinocyte terminal differentiation. J Biol Chem 2003; 278:17792-17799.
29. Ioannidis JPA, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis GC. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361:567-571.